Redefining the role of biomarkers in heart failure trials: expert consensus document.

Published

Journal Article (Review)

Heart failure is a growing cardiovascular disease with significant epidemiological, clinical, and societal implications and represents a high unmet need. Strong efforts are currently underway by academic and industrial researchers to develop novel treatments for heart failure. Biomarkers play an important role in patient selection and monitoring in drug trials and in clinical management. The present review gives an overview of the role of available molecular, imaging, and device-derived digital biomarkers in heart failure drug development and highlights capabilities and limitations of biomarker use in this context.

Full Text

Duke Authors

Cited Authors

  • Kramer, F; Sabbah, HN; Januzzi, JJ; Zannad, F; Peter van Tintelen, J; Schelbert, EB; Kim, RJ; Milting, H; Vonk, R; Neudeck, B; Clark, R; Witte, K; Dinh, W; Pieske, B; Butler, J; Gheorghiade, M

Published Date

  • May 2017

Published In

Volume / Issue

  • 22 / 3

Start / End Page

  • 263 - 277

PubMed ID

  • 28332132

Pubmed Central ID

  • 28332132

Electronic International Standard Serial Number (EISSN)

  • 1573-7322

Digital Object Identifier (DOI)

  • 10.1007/s10741-017-9608-5

Language

  • eng

Conference Location

  • United States